Health Care • Medical Specialities
$15.82 ▼ -0.10
(-0.66%)
MKT CAP: $1.70B • VOL: 2.36M
52W L $5 52W H $19
PSNL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $69.6M | $84.6M | $73.5M |
| YoY Revenue Growth % | -17.7% | +15.2% | — |
| Gross Profit | $15.8M | $26.8M | — |
| Gross Margin % | 22.7% | 31.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$88.1M | -$68.3M | -$109.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$81.3M | -$81.3M | -$108.3M |
| EBITDA (Normalized) | -$84.5M | -$67.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$74.9M | -$45.1M | -$56.3M |
| Capital Expenditures (CapEx) | $4.5M | $1.6M | — |
| Free Cash Flow (FCF) | -$79.5M | -$46.8M | -$56.3M |
| FCF Margin % | -80.0% | -55.3% | -76.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $124.2M | $91.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $261.2M | $203.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PSNL.